Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gutzmer, R; Becker, JC; Enk, A; Garbe, C; Hauschild, A; Leverkus, M; Reimer, G; Treudler, R; Tsianakas, A; Ulrich, C; Wollenberg, A; Homey, B.
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
J Dtsch Dermatol Ges. 2011; 9(3):195-202
Doi: 10.1111/j.1610-0387.2010.07561.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in the treatment of various entities of malignant tumors. Patients treated with EGFR inhibitors very likely develop cutaneous side effects. The development of a papulopustular, follicular exanthema during the first weeks of therapy correlates with therapeutic benefit. However, this exanthema and other cutaneous side effects can impair the quality of life of the patient and might limit the therapy with the EGFR inhibitor. For an optimal therapeutic benefit and quality of life an adequate management of cutaneous side effects is necessary. A panel of German dermatologists developed on the basis of personal experience and current literature consensus recommendations for the management of cutaneous side effects of EGFR inhibitors.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - adverse effects
- Dermatology - standards
- Drug Eruptions - diagnosis
- Epidermal Growth Factor - antagonists and inhibitors
- Epidermal Growth Factor -
- Humans -
- Practice Guidelines as Topic -
- Primary Health Care - standards
- Find related publications in this database (Keywords)
- EGFR
- cutaneous side effects
- papulopustular exanthema